Floatz logo

Therapeutic Asset Ratings

395 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Naptumomab Estafenatox
Prostate Cancer
NeoTX Therapeutics Ltd.P1C (36)
ngm438
Prostate Cancer
NGM Biopharmaceuticals, IncP1C (36)
ngm831
Prostate Cancer
NGM Biopharmaceuticals, IncP1C (36)
-Nota-Psmai-Peg-Cy5.5-C' Dot Tracer
Prostate Cancer
Memorial Sloan Kettering Cancer CenterP1C (36)
Nuv-868
Prostate Cancer
Nuvation Bio Inc.P1C (36)
Obinutuzumab
Prostate Cancer
NeoTX Therapeutics Ltd.P1C (36)
Oct-598
Prostate Cancer
Oscotec Inc.P1C (36)
Ovm-200
Prostate Cancer
Oxford Vacmedix UK Ltd.P1C (36)
Pgv-001
Prostate Cancer
Ashutosh Kumar TewariP1C (36)
Psw-1025
Prostate Cancer
Osaka UniversityP1C (36)
QXL138AM
Prostate Cancer
Nammi Therapeutics IncP1C (36)
RITONAVIR
Prostate Cancer
University of ChicagoP1C (36)
Stm-416P
Prostate Cancer
SURGE TherapeuticsP1C (36)
syn818
Prostate Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdP1C (36)
TH19P01-DOCETAXEL
Prostate Cancer
TheratechnologiesP1C (36)
tj101
Prostate Cancer
Phrontline BiopharmaP1C (36)
Unicar02-T-Ppsma
Prostate Cancer
AvenCell Therapeutics, Inc.P1C (36)
Xaluritamig
Prostate Cancer
AmgenP1C (36)
YS5 antibody
Prostate Cancer
Robert Flavell, MD, PhDP1C (36)
Zirconium Zr 89-Dfo-Ys5
Prostate Cancer
Robert Flavell, MD, PhDP1C (36)
zm008
Prostate Cancer
Zumutor Biologics Inc.P1C (36)
68ga-nta-476
Prostate Cancer
Melbourne Theranostic Innovation CentreEarly P1C (36)
Psma-Targeted [In-111]-Labeled Trillium Compound
Prostate Cancer
Ratio Therapeutics, Inc.Early P1C (36)
Pti-122
Prostate Cancer
Ratio Therapeutics, Inc.Early P1C (36)
Xentuzumab
Prostate Cancer
University of OxfordEarly P1C (36)
Showing 326 to 350 of 395 assets
PreviousPage 14 of 16Next